These and other Duke-Margolis efforts have been made possible in part by:

SESSION: The Path Forward for Emergency Response

The end of an officially declared COVID-19 Public Health Emergency (PHE) in the United States is not the end of the ongoing threat posed by the virus – nor the final word in America’s overall ability to prepare for and respond to the next major health threat. While an often fragmented response during the acute phases of the pandemic laid bare many structural and coordination challenges that need addressing, it also provided glimmers of hope in areas like the rapid development of medical technologies (including diagnostic tests, therapeutics, and vaccines) that can be emulated again. Absent a formal bipartisan Congressional or Presidential commission, all stakeholders will need to sift through these painful and productive lessons at all levels – Federal, state and local, public and private – to help inform near term legislative opportunities like expected 2023 reauthorization of the Pandemic and All Hazard Preparedness Act (PAHPA) and longer term strategic investment in our shared national response capabilities.

Duke-Margolis Spotlights

Strengthening Preparedness and Response

Together with the Healthcare Leadership Council, Duke-Margolis has outlined key actions for private and public sector leaders to take together in order to better prepare the U.S. for future public health emergencies across two 2021 and 2023 reports:

• National Dialogue For Healthcare Innovation: Framework for Private-Public Collaboration on Disaster Preparedness and Response
• Framework for Disaster Preparedness and Response: Updated

Building Data Infrastructure and Testing Strategies for the Future

From early in the COVID-19 pandemic, Duke-Margolis understood the importance of widespread and efficient testing capacity and how this would continue to be a major pillar in mitigation strategies even after the availability of vaccines. Duke-Margolis has issued numerous papers on how testing can be made more widespread, accessible, and effective, including 2023 recommendations for a national strategy moving forward:

• Testing for Respiratory Infections: Beyond the COVID-19 Public Health Emergency
• Informing Local Emergency Response Through Standard Health Care Data Reporting

Preparing an Updated Armamentarium

Innovative medical technologies will be needed for sustained monitoring of and response to COVID-19, as well continued work to outpace drug-resistant infections and antimicrobial resistance. In partnership with the Gates Foundation, Duke-Margolis has launched a two-year effort to specifically advance regulatory and coverage policy considerations around a potential class of new medical technologies focused on population-level transmission reduction or blocking – and how these types of technologies may change comprehensive public health and health care efforts to curb infections. The first year of this work will culminate in a public report and conference in the Fall of 2023.